全文获取类型
收费全文 | 7896篇 |
免费 | 570篇 |
国内免费 | 19篇 |
专业分类
耳鼻咽喉 | 88篇 |
儿科学 | 355篇 |
妇产科学 | 165篇 |
基础医学 | 943篇 |
口腔科学 | 176篇 |
临床医学 | 1464篇 |
内科学 | 1319篇 |
皮肤病学 | 72篇 |
神经病学 | 804篇 |
特种医学 | 93篇 |
外科学 | 673篇 |
综合类 | 115篇 |
一般理论 | 10篇 |
预防医学 | 1019篇 |
眼科学 | 171篇 |
药学 | 532篇 |
1篇 | |
中国医学 | 6篇 |
肿瘤学 | 479篇 |
出版年
2023年 | 77篇 |
2022年 | 60篇 |
2021年 | 150篇 |
2020年 | 111篇 |
2019年 | 157篇 |
2018年 | 190篇 |
2017年 | 115篇 |
2016年 | 138篇 |
2015年 | 176篇 |
2014年 | 261篇 |
2013年 | 439篇 |
2012年 | 576篇 |
2011年 | 613篇 |
2010年 | 311篇 |
2009年 | 300篇 |
2008年 | 465篇 |
2007年 | 562篇 |
2006年 | 498篇 |
2005年 | 532篇 |
2004年 | 468篇 |
2003年 | 440篇 |
2002年 | 417篇 |
2001年 | 86篇 |
2000年 | 106篇 |
1999年 | 94篇 |
1998年 | 95篇 |
1997年 | 77篇 |
1996年 | 47篇 |
1995年 | 70篇 |
1994年 | 52篇 |
1993年 | 64篇 |
1992年 | 55篇 |
1991年 | 67篇 |
1990年 | 51篇 |
1989年 | 35篇 |
1988年 | 41篇 |
1987年 | 40篇 |
1986年 | 27篇 |
1985年 | 39篇 |
1984年 | 40篇 |
1983年 | 41篇 |
1982年 | 48篇 |
1981年 | 34篇 |
1980年 | 25篇 |
1979年 | 25篇 |
1978年 | 17篇 |
1977年 | 19篇 |
1975年 | 14篇 |
1969年 | 14篇 |
1968年 | 13篇 |
排序方式: 共有8485条查询结果,搜索用时 15 毫秒
31.
Fosinopril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in essential hypertension. 总被引:4,自引:0,他引:4
Fosinopril is a phosphinic acid prodrug which, after oral administration, undergoes rapid hydrolysis to its active diacid, the angiotensin converting enzyme (ACE) inhibitor fosinoprilat. Unlike other ACE inhibitors, fosinoprilat has a compensatory dual route of elimination and is cleared by the liver and kidneys. Thus, in patients with diminished renal function increased hepatic clearance of fosinoprilat is noted and, similarly, in patients with diminished hepatic function increased renal clearance seems to occur. Because of this compensatory elimination, fosinopril therapy for all patients can begin with the same recommended dosage. Fosinopril 10 to 40mg administered once daily is an effective antihypertensive regimen that has shown efficacy similar to that of enalapril 5 to 10 mg/day, propranolol 80 to 160 mg/day, hydrochlorothiazide 25 to 50 mg/day and sustained release nifedipine 40 mg/day in preliminary clinical trials. Generally, fosinopril is well tolerated and adverse events associated with the drug are usually mild and similar to those associated with other ACE inhibitors. Thus, fosinopril appears to be a useful alternative to certain 'established' agents used for treating patients with essential hypertension. 相似文献
32.
33.
Because organ transplantation is the preferred treatment for organ failure, the demand for human organs for transplantation is large and growing. From this demand, several fields based on new technologies for the replacement or repair of damaged tissues and organs have emerged. These fields include stem cell biology, cloning, tissue engineering and xenotransplantation. Here we evaluate the potential contribution of these to the devising of alternative approaches to organ replacement. We present our vision for the development of two structurally complex organs – the lung and the kidney – based on a 'fusion' of new and established technologies. 相似文献
34.
35.
Carol Smillie B.N. B.Ed. M.S.C. Katherine Coffin B.A. ME.D. Kathryn Porter B.A. Brenda Ryan B.A. M.B.A. 《Journal of community health》1988,13(3):156-170
The International Conference on Primary Health Care, meeting in Alma-Ata, in the Soviet Union, September 12, 1978, expressed the need for urgent action by all governments, all health and development workers and the world community, to protect and promote the health of all people of the world. The world was caught by the phrase which emerged from this conference, Health For All by the Year 2000 and many have examined the articles of the Alma-Ata declaration and tried to implement them in their corner of the world. This paper describes a community-based smoking-cessation program which was implemented in the province of Nova Scotia, Canada, during the years 1980–1984. Primary to this project was the belief that people have the right and the duty to participate individually and collectively in planning and implementing their health care. This paper describes one community's effort in putting this belief into practice.Carol Smillie, B.N. BE.d. M.S.c. is an Assistant Professor at the School of Nursing, Dalhousie University, Halifax, Nova Scotia, Canada B3H 3J5, Katherine Coffin, BA, MEd is the Program Officer, Nova Scotia Office, Health Promotion Directorate Health and Welfare Canada, 5251 Duke Street, Halifax, Nova Scotia. Canada B3J 1P3. Kathryn Porter, B.A. (Gen)., is the Information and Education Coordinator, Nova Scotia Division Canadian Cancer Society. Brenda Ryan, B.A., M.B.A. is Program Evaluation Analysist, Nova Scotia Department of Health, 6088 Hollis Street, Halifax. Nova Scotia, Canada. This Project was funded by Health and Welfare Canada, Nova Scotia Department of Health, Nova Scotia Division Canadian Cancer Society, Requests for reprints should be addressed to: Professor Carol Smillie. 相似文献
36.
Tissue distribution metabolism and excretion of 2,2′,4,4′, 5-pentachlorodiphenyl ether in the rat 总被引:1,自引:0,他引:1
E. Komsta I. Chu D. C. Villeneuve F. M. Benoit D. Murdoch 《Archives of toxicology》1988,62(4):258-262
The tissue distribution, metabolism and excretion of 14C-2,2,4,4,5-pentachlorodiphenyl ether (PCDE) were studied in the rat. Radioactivity was distributed in all tissues examined, with the highest concentrations being found in the fat followed by the skin, liver, kidney and muscle. Most of the radioactivity found in the tissues was due to unchanged PCDE. Decay of PCDE in the blood was fitted to a four-compartment pharmacokinetic model, and the last compartment had a half-life of 5.8 days. A total of 55% and 1.3% of an orally administered dose was excreted in feces and urine, respectively, in 7 days. More than 64% of the fecal radioactivity was due to unchanged PCDE, while hydroxylated PCDE accounted for 23%. 相似文献
37.
Martin A. Graham David R. Newell Brenda J. Foster A. Hilary Calvert 《Cancer chemotherapy and pharmacology》1989,23(1):8-14
Summary CI-941 is a new synthetic DNA-binding agent selected for phase I clinical evaluation. The drug has broad-spectrum antitumour activity against a number of murine tumours and, in contrast to doxorubicin, is unlikely to induce cardiotoxicity by a free-radical-mediated mechanism. In this study the toxicity and pharmacokinetics of CI-941 were studied in the mouse to enable the implementation of a pharmacokinetically guided dose-escalation strategy in patients. Following a single i.v. bolus injection in mice, CI-941 induced dose-dependent leukopenia. The white blood cell counts were suppressed on day 3 by 18%, 50% and 65% of control, at doses of 10, 15 and 20 mg/kg CI-941, respectively. Other toxicities such as weight loss, alopecia, diarrhoea and convulsions were observed at doses >20 mg/kg. Lethality studies in female Balb-c mice resulted in an LD10 value of 20 mg/kg (95% confidence limits; range, 19–21 mg/kg) and an LD50 value of 22 mg/kg (95% confidence limits; range, 21–23 mg/kg). The pharmacokinetics of CI-941 were studied at four dose levels from 1/10 of the LD10 to the LD10 (20 mg/kg). The drug was rapidly cleared from the plasma (250–400 ml/min per kg) at a rate approaching the cardiac output of mice, displaying triphasic plasma pharmacokinetics. The area under the plasma CI-941 concentration vs time curve (AUC) was linear with respect to the dose, up to and including 15 mg/kg (AUC=110 M x min at 15 mg/kg), but became non-linear at 20 mg/kg (AUC=277 M x min). Despite 80%–84% plasma protein binding, CI-941 was rapidly and extensively distributed into tissues, especially the kidney. Following i.v. bolus injections at doses of 1.5 and 15 mg/kg, elimination of the parent compound by urinary excretion accounted for 12%–18% of the delivered dose. A phase-I starting dose (based on that equivalent to 1/10 of the LD10 in the mouse) of 5 mg/m2 CI-941 is recommended for single administration schedules. In addition, a pharmacokinetically guided dose-escalation strategy, based on achieving a target AUC of 110 M x min, is proposed. 相似文献
38.
Peter H. Gilligan L. R. McCarthy Brenda K. Bissett 《Journal of clinical microbiology》1981,13(4):643-645
A case report describing Capnocytophaga ochracea (Bacteroides ochraceus) septicemia in a 21-year-old male patient receiving chemotherapy for acute lymphocytic leukemia is presented. The unusual features of this organism are discussed together with a review of the literature. 相似文献
39.
A. Bartoli Brenda A. Cross A. Guz S. K. Jain M. I. M. Noble Diana W. Trenchard 《The Journal of physiology》1974,240(1):91-109
1. The inhalation of CO(2) produces a tachypnoea only in the presence of intact vagus nerves; the present study was designed to examine the mechanism of this phenomenon in the dog.2. Closed-chest cardiopulmonary bypass was established in dogs weighing 16-24 kg, anaesthetized with chloralose. When the ;bypass' was established pulmonary blood flow ceased, P(A, CO2) was reduced and the respiratory rate slowed. 3-10% CO(2) in O(2) could then be inhaled without change in the level of P(a, CO2) set at the oxygenator.3. The addition of CO(2) in these concentrations to the inspired oxygen resulted in an increase in respiratory frequency, maximal at the first breath and sustained for the 1 min period of exposure. The increase in respiratory frequency was due to a shortening of expiratory duration. Inspiratory duration did not change. The response was absent after vagotomy.4. Inert gases in O(2), given as a control, had no effect on breathing.5. The effect of raising P(a, CO2) (by increasing the concentration of CO(2) in the gas equilibrating the blood in the oxygenator), was primarily to increase tidal volume.6. The ventilatory effect of inspiring CO(2)/O(2) mixtures was shown to be additive to the effect of raising P(a, CO2).7. These experiments show that an afferent vagal reflex originating from the lungs causes tachypnoea, when a dog, on ;bypass', inhales low concentrations of CO(2) in O(2). 相似文献
40.